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established by subcutaneously injecting K562 cells into nude mice. Our findings revealed that HH-GV-678 significantly, and in a dose-dependent manner, inhibited the growth of K562 xenografts and induced regression in all tumors at a daily dose of 75 mg/kg for nine days. In contrast, imatinib only induced regression in two of eight tumors at a daily dose of 300 mg/kg (150 mg/kg, twice a day) for 14 days (Figure 2a ). In addition, HH-GV-678 significantly improved the body weight of tumorbearing mice. These effects of HH-GV-678 could translate into a survival benefit for tumor-bearing mice. As shown in Figure 2b , vehicle-treated mice largely died owing to rapid growth of the K562 xenografts, and had a median survival time of 25.5 days. The HH-GV-678 treatment effectively and dose-dependently inhibited tumor growth and prolonged the survival of these tumor-bearing mice. The median survival time was prolonged from 25.5 to 47.5 days when mice were given a daily dose of 75 mg/kg for 14 days. In contrast, imatinib prolonged the median survival time from 25.5 to 33 days when mice were given a daily dose of 300 mg/kg (150 mg/kg, twice a day). Most mice died before day 42; however, two of eight mice in the group who were receiving 75 mg/kg HH-GV-678 remained alive without any observable tumors on day 60.
To investigate the efficacy of HH-GV-678 against imatinibresistant CML in vivo, we established a systemic CML model by injecting imatinib-resistant 32D-H396P cells into the tail veins of nude mice. Mice injected with 32D-H396P cells became morbid, developed hind-leg paralysis and died within 14-15 days. Pathological studies revealed that these mice were seriously hepatomegalic (that is, 1.94-fold in weight) and splenomegalic (that is, 6.0-fold in weight) compared with normal mice. Treatment with HH-GV-678 for 13 days (100 mg/kg) significantly blocked the hind-leg paralysis, and reduced the hepatomegaly (P ¼ 0.002) and splenomegaly (P ¼ 0.03) in these leukemic mice (Supplementary Figure 4) . Consistent with the results described above, the survival of HH-GV-678-treated mice was significantly prolonged compared with both untreated and imatinib-treated mice (Figure 2c) .
To elucidate the potential mechanisms underlying the superior antitumor effects of HH-GV-678, we compared the effects of HH-GV-678 and imatinib on Bcr-Abl autophosphorylation in K562 xenograft tissues. Treatment with HH-GV-678 significantly inhibited Bcr-Abl phosphorylation within 2 h after treatment, and this inhibitory effect was maintained for 24 h at a dose of 75 mg/kg. In contrast, and consistent with previous findings, 3 although imatinib (150 mg/kg) inhibited Bcr-Abl phosphorylation within 2 h of drug treatment, this inhibition only lasted for 6 h (Supplementary Figure 5) . We believe that the differential effect on target inhibition may contribute to the superior antitumor effects of HH-GV-678.
In conclusion, we have characterized HH-GV-678 as a novel inhibitor of Bcr-Abl that significantly inhibits Bcr-Abl activity, overrides imatinib resistance mediated by point mutations in Bcr-Abl and notably outperforms imatinib both in vitro and in vivo. Thus, our findings suggest that HH-GV-678 is a promising candidate for the treatment of CML, particularly for patients who develop imatinib resistance as a result of mutations in the Bcr-Abl kinase domain. Currently, HH-GV-678 is undergoing phase I clinical trials in China.
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Somatic gain-of-function mutation of the Janus kinase (JAK2) gene (NM_004972.2: c.1849G4T transversion resulting in V617F) has been identified in BCR-ABL-negative chronic myeloproliferative neoplasms (MPNs) (in 495% of polycythaemia vera (PV), and in 40-60% of essential thrombocythaemia (ET) and primary myelofibrosis (PMF)). The inherited genetic background of an individual patient has been long predicted to influence disease susceptibility and phenotype in MPN. Recent studies have demonstrated that the presence of JAK2 V617F is associated with an inherited JAK2 haplotype designated as '46/1' haplotype. [1] [2] [3] Carriers of the 46/1 haplotype have higher risk of acquiring JAK2 V617F mutation, but the role of 46/1 haplotype as a predisposition factor for V617F-negative MPN is still remained controversial. Only a few studies 4, 5 by LightCycler technology applying melting curve analysis with hybridization probe detection format. C allele frequency and 95% confidence interval (CI) of rs12343867 is presented as 46/1 haplotype frequency. JAK2 V617F mutation detection was performed before the JAK2 rs12343867 genotyping in all patients. JAK2 V617F mutation-negative PV cases, and V617F-positive AML cases were not included in the MPN or AML groups, respectively. As archived germline tissue was not available in our MPN study population, an alternative method (617F-and 617V-specific amplification of JAK2 alleles) was applied. The 617V-specific amplification in V617F-positive cases allowed the detection of the V617F-non-affected allele in heterozygous cases. Appropriate negative controls (JAK2 V617F-negative samples in 617F and homozygous V617F HEL cell line DNA in 617V-specific amplification) were included in each PCR round.
The frequency of JAK2 V617F was 80.4% (251/312) in the MPN group: 100% (153/153) in PV patients, 59.5% (78/131) in ET patients, and 71.4% (20/28) in PMF patients. Among 251 V617F-positive MPN cases, 57 and 50 cases gave identically TT or CC genotypes both by 617F-and 617V-specific amplification, therefore these samples were designated as TT and CC germline genotypes. A total of 144 cases designated as CT germline genotype showed different melting curves on 617F-and 617V-specific amplifications. 617F-specific amplification showed CC genotype in 85% (122/144), TT in 13% (19/144) and CT in 2% (3/144) of heterozygous cases. Similarly to previous reports, [1] [2] [3] our results indicated that V617F mutation preferentially arose on 46/1 haplotype, and can be rarely acquired independently twice in the same patient.
We confirmed that the 46/1 haplotype ('C' allele of rs12343867) is a predisposition factor for JAK2 V617F-positive MPN. Increased haplotype frequency was found in the entire, unselected MPN group, and in each MPN subgroups according to diagnosis (PV, ET, PMF) compared with controls ( Table 1 ). The 46/1 haplotype frequency was significantly higher in V617F-positive MPN, compared with V617F-negative MPN (P ¼ 0.006; odds ratio (OR): 1.28 (1.09-1.49)). As previous studies [4] [5] [6] described an increase in 46/1 haplotype frequency according to increasing JAK2 V617F allele burden, our finding was possibly influenced by the presence of MPN patients with high V617F allele burden. The role of 46/1 haplotype as a predisposition factor for V617F-negative MPN has initially been debated. [1] [2] [3] Although in our cohort, the haplotype frequency did not differ between V617F-negative MPN (ET and PMF) and local [4] [5] [6] [7] [8] As 46/1 haplotype predisposes for the acquisition of JAK2 V617F mutation, it may influence MPN signs and symptoms. Similarly to recent studies, 4-8 we also did not find differences in age, sex and relevant prognostic clinical parameters (hemoglobin, blood cell counts), occurrence of vascular complications (venous and arterial thrombosis, hemorrhage) or leukemic transformation according to 46/1 genotypes in PV, ET and PMF ( Table 2 ). The only MPN complication, which had a different frequency among 46/1 genotype groups, was myelofibrosis (PMF or post-PV/ET myelofibrosis): 32% of 'CC' homozygotes versus 12% of non-CC individuals (P recessive ¼ 0.001). Post-PV/ET myelofibrosis was also more frequent among patients with CC versus non-CC genotypes in V617F-positive PV and ET patient subgroups (18% (8/44 CC) versus 5% (12/234 non-CC) patients, P ¼ 0.006). We hypothesize that, clonal cells carrying 46/1 haplotype in homozygous form might be more susceptible to somatic recombination resulting in uniparental disomy compared with 46/1 heterozygous cells, because of the perfect match between large portions (approximately 280 kb corresponding to the haplotype block) of the two parental 9p chromosome regions. JAK2 V617F homozygous patients with PV or ET have more frequent evolution into secondary myelofibrosis compared with heterozygous counterparts. Interestingly, similar tendency was observed among V617F-negative ET and PMF patients, that is, the presence of myelofibrosis or transformation to myelofibrosis occurred more frequently among 46/1 CC homozygotes (50% (2/4 CC) versus 12% (7/57 non-CC)), but this observation can not be interpreted because of the low case numbers.
In all, 339 patients with V617F-negative AML were also enrolled to investigate the relationship between the development of leukemia and 46/1 haplotype. In the entire, unselected AML group (n ¼ 339), the 'C' allele frequency (28.9±3.5%) did not show significant difference compared with controls. The preferential acquisition of JAK2 mutations raises the possibility that the presence of the 46/1 haplotype confers genomic instability. To test the potential relationship of the 46/1 haplotype with different mutational mechanisms, we compared the genotype distribution of rs12343867 in different AML subgroups (separated by karyotype changes; fms-like tyrosine kinase 3 or nucleophosmin 1 mutations). According to karyotype, 19% of patients (59/317) belonged to the good prognostic group (30 patients with t(15;17), 16 patients with t(8;21), 13 patients with inv(16)), 54% of patients (172/317) belonged to the intermedier prognostic group (129/172 had normal karyotype) and 27% of patients (86/317) belonged to the poor prognostic group. Altered 46/1 haplotype frequency was observed in AML patients with and without normal karyotype (NK) (32.9 ± 5.9% versus 25.0 ± 4.5%, P ¼ 0.0313, OR 1.47 (1.04-2.09)). In a multivariate analysis, carriership for the 46/1 haplotype was associated with NK-AML compared with non-NK-AML, independently of age and sex (P ¼ 0.01, adjusted OR: 1.8; 95% CI: 1.14-2.83). Younger NK-AML patients had a tendency of higher haplotype frequency than controls (NK-AMLo55 year AF ± 95% CI: 35.6 ± 7.1%, NK-AMLo45 year 36.4±10.3%), whereas patients with abnormal karyotype had similar 46/1 haplotype frequency to controls regardless of Table 2 Clinical and laboratory characteristics of MPN patients according to JAK2 rs12343687 genotypes TT (42) CT (69) CC (20) TT (8) CT (11) CC ( Letters to the Editor age ( Table 1 ). The haplotype frequency of NK-AML cohort under the age of 55 or 45 years was not significantly different compared with local controls (allelic model (C versus T alleles), P allelic in Table 1 ). On comparing carrier frequencies (dominant model, that is, combination of C allele carriers (CC and CT genotypes) versus non-carriers (TT genotype)), a tendency toward increased frequency of 46/1 haplotype carriers (Table 1 , NK-AML o45 years P dominant ¼ 0.0361, OR (95% CI): 2.09 (1.08-4.05), Figure 1 ) was observed. In multifactorial diseases (like leukemogenesis) the genetic background has more pronounced role in the development of the disease at a younger age, whereas the accumulation of multiple acquired risk factors provides a continuously increasing contribution to the formation of the same disease in older individuals. There was no difference in JAK2 46/1 genotype distribution in FLT3 internal tandem duplication, tyrosine kinase domain mutation, and NPM1-positive and -negative subgroups in the entire AML and in the NK-AML group.
The exact pathomechanism, how 46/1 haplotype predispose for the acquisition of V617F mutation is unknown. Two possible hypotheses were proposed: 9 (i) the 'hypermutability hypothesis' suggests genomic instability at the JAK2 locus, whereas (ii) the 'fertile ground hypothesis' suggests that cells carrying the 46/1 haplotype gain selective advantage in situations, when oncogenic mutations occur. Detection of increase in 46/1 haplotype frequency not only in JAK2 mutation-positive MPN, but in JAK2 V617F-negative MPN and also in NK-AML (this study) supports the 'fertile ground hypothesis'. Two recent reports attempted to show associations between the presence of the 46/1 haplotype and further genetic alterations having a role in leukemogenesis located on other chromosome by focusing on MPL mutations in patients with ET. Patnaik et al. 7 did not find an increased 46/1 allele frequency in V617F-negative, MPL mutation-positive ET patients (n ¼ 22). Neither could Jones et al. 8 demonstrate a significantly increased 46/1 allele frequency in a similar patient group (n ¼ 32, P ¼ 0.06). However, a meta-analyses of different patient groups with diverse ethnic background resulted in a significantly increased OR. 8 Our results suggest that MPN and NK-AML, but not AML with various cytogenetic alterations (non-NK-AML) may share common pathogenetic mechanisms (the importance of subtle functional difference in JAK2 signaling caused by 46/1 haplotype). In the light of these recent data, we believe that our novel and somewhat unexpected findings in AML may indicate subtle variations in leukemia susceptibility, which certainly requests further studies with larger patient cohorts to increase statistical power.
In conclusion, our study confirms earlier observations that JAK2 46/1 haplotype is a susceptibility factor for JAK2 V617F-positive MPN and lends further support that, it is a potential common inherited susceptibility factor for JAK2 V617F-negative MPN and NK-AML. The 46/1 haplotype is not associated with MPN manifestations, like disease type, splenomegaly, signs of increased erythropoiesis or myelopoiesis and vascular complication, except the increased risk of the development of myelofibrosis in homozygous cases.
Carrier frequency (%) Figure 1 Carrier frequencies of 46/1 haplotype in different AML subgroups stratified according to karyotype and age at diagnosis. Fischer's Exact test was used for p value calculations, in which the distribution of non-carriers (TT) and carriers of the 46/1 haplotype (rs1234867 CT and CC genotypes combined) were compared between each patient and control groups with the resulting p values indicated on the figure. Bars on the columns indicate 95% CI. The case numbers (n) are indicated under the columns.
Nucleophosmin (NPM1) is a nucleocytoplasmic shuttling protein, which is mutated in approximately 30% of acute myeloid leukemia (AML). 1 In leukemia, mutations are typically found in exon 12 of the NPM1 gene, leading to ectopic cytoplasmic expression of the protein (normally found in the nucleolus) due to changes of two crucial C-terminal tryptophan(s) and generation of a novel nuclear export signal.
2,3 The aberrant nuclear export of the NPM1 protein and its accumulation in the cytoplasm is detectable by immunohistochemistry. [2] [3] [4] Because of its distinctive biological, clinical and prognostic features 5, 6 'AML with mutated NPM1' has been included as a provisional entity in the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues. 7 Of importance, AML with NPM1 mutations but without FLT3-ITD seem to benefit from a new upfront therapy concept including all-trans retinoic acid evaluated for elderly patients 8 and recently under investigation in AML patients under the age of 60.
NPM1 mutations can be detected on the molecular level using direct sequencing, high-resolution fragment analysis, melting curve analysis and denaturing-high performance liquid chromatography (dHPLC). 5 Recently, a western blot assay using polyclonal antibodies for specific identification of the mutant protein variant-A was described. 5 Furthermore, cytoplasmic nucleophosmin (NPMc) may be detected by immunohistochemistry in paraffin-embedded bone marrow (BM) trephines. [2] [3] [4] However, molecular procedures use rather sophisticated and expensive equipment and are time-consuming, whereas BM biopsies are not routinely performed for AML and take longer for decalcification and preparation. We reasoned that because of the cytoplasmic delocalization, the NPM1 protein, which is normally restricted to the nucleolus, might also be accessible for intracellular flow cytometry. The aim of this study was to develop and validate a rapid method on the basis of flow cytometric detection of NPMc as surrogate for NPM1 mutations.
To this end, fresh BM or peripheral blood samples from newly diagnosed AML patients (training set: n ¼ 215; validation set: n ¼ 83), enrolled in different German multicenter trials of the Study Alliance Leukemia, were examined by central routine leukemia diagnostics as well as flow cytometric testing for NPMc expression. BM of healthy donors and the cell lines OCI-AML3 (carrying NPM1 mutation-A) and MV4-11 (carrying the germline NPM1 gene) served as controls (Supplementary Information). To identify the optimal flow cytometric procedure for NPMc detection, five monoclonal antibodies, recognizing both mutant and wild-type NPM1 proteins, were tested (Supplementary Table S1 ). The non-conjugated NPM1 antibodies and the respective isotype controls (Abcam, Cambridge, UK) were labeled with PE (phycoerythrin) using a commercial labeling kit (Zenon; Invitrogen, Karlsruhe, Germany). Thus, all NPM1 antibodies were titrated achieving the best fluorescence signal-to-noise-ratio. A four-color immunophenotyping procedure was performed. First, the cell surface was stained with CD45FITC (fluorescein isothiocyanate; Biozol, Esching, Germany), CD34PerCP5.5 (peridinin chlorophyll 5.5) and CD117APC (allophycocyanin; BD Biosciences, San Jose, CA, USA). Second, staining with the PE-prelabeled NPM1 antibody was done using a Fix and Perm Kit (Biozol, Esching, Germany). This kit is routinely applied for the detection of cytoplasmic antigens, for example, cyCD3 or cyMPO, as well as nuclear antigens, for example, TdT. Leukemic blasts were gated on the basis of CD45 expression and side scatter. If possible, the appropriate gate setting was evaluated by backgating CD34 pos or CD117 pos events. In normal BM, CD34 and CD117 expression was mandatory for normal precursor/progenitor cell gate setting. For evaluating the NPMc expression in the non-blasts (granulo-, mono-, erythro-, lymphopoiesis) the respective cell populations were gated according to their CD45 expression and side scatter properties. The mean fluorescence intensity (MFI) of NPMc was assessed as ratio of the fluorescence intensity of NPM PE and the respective isotype control (Figure 1a ). Molecular NPM1-and FLT3-ITD mutational screening was performed in parallel, as previously described 9 ( Figure 2) .
Of the five antibodies, the one with a sufficiently high difference in the MFI comparing the OCI-AML3 cells (with NPM1 mutation) and MV4-11 cells (with the wild-type NPM1 gene) was clone 5E3 (Supplementary Table S1 ), which was chosen for all further investigations. Interestingly, this was one of the two antibodies directed against the C-terminal part of the protein, which might be important for flow cytometric detection of NPMc. Normal precursor/progenitor cells of healthy BM donors showed a low NPMc expression comparable to that of MV4-11 cells. On the basis of a median MFI þ 2 standard deviations of 7.2, calculated after the analysis of progenitor cells in 23 BM donor samples, the NPMc fluorescence was defined positive in patients with a MFI48.0. This threshold was also confirmed using the Youden's Index (Table 1 and Figures 1d and e) . AMLs with mutated NPM1 frequently show multi-lineage involvement (myelo-, mono-, erythro and megakaryopoiesis) 10 (Supplementary Table S2 Table S2 ). This indicates that yet unknown nucleocytoplasmic interactions might be responsible for NPM1 antibody binding in
